Simply Wall St posts a $345/sh long term pt. This is significant over what "invested" capital firms say, as they have no skin in the game, just evaluate fairly. It's also very realistic now that the breakthrough on spine treatment has been made.​

-A Breakthrough Product: NOCISCAN is the first SaaS platform of its kind to offer a noninvasive method for physicians to assess lumbar spine discs, leveraging cloud technology to process and analyze MRI data for this purpose. Aclarion's focus on optimizing clinical treatments through advanced technology aligns with a growing trend in healthcare towards personalized medicine.

-Recent Positive Balance Sheet News: Aclarion terminates ATM!  As further dilution is not needed, Aclarion has terminated its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, ending its need to sell shares of its common stock through any new offering.

-A Colorado company-- so no mystery financials as with foreign firms....and no tariff worries!

-Post RS split "Re-positioning" is DUE THIS WEEK...Every US stock with at least decent financials (Acon's are clearly more than decent) experiences a re-evaluation by Hedge Funds and Institutions and a large, sudden "spike" occurs within 30-35 days.

Also, investors must realize:

 Just because the ticker symbol is "ACON" don't think for a moment this stock is "a con". That's simply childish and immature thinking. This company has set in motion great things in the medical space - partnerships with Scripps & RadNet. HUGE. 

Curr $7.50 Our PT=$46.39 (618% realistic upside potential.)

​

#2 RSLS ReShape Lifesciences® +1 spot

A newcomer to our list, RSLS has our attention with not only the

bargain basement price from the April 1st at $1.58/sh price,

but upcoming events as well.

The catalysts are there, as the merger with Vyome is due soon,

and the April 9th PR of "ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market". Partnering with Israel-based Motion Informatics to exclusively import and distribute their next-generation neuromuscular rehabilitation devices in the U.S.

Their flagship product, the Stimel-03, was showcased at the American Occupational Therapy Association 2025 Annual Conference and Expo, held April 3-5, 2025, in Philadelphia, PA.

This is an FDA APPROVED game changer for RSLS, anyone who

sells their shares in the light of this has no business investing,

as they are also financial stable: Per DT: "The company has 13.8 months of cash left based on quarterly cash burn of -$1.11M and estimated current cash of $5.1M."

That translates to $.46/sh in CASH alone, not including this

budding --and now A.I. driven-- health care superstar. 

 Curr=$.3663 PT =$2.85 (778% realistic upside potential.)

 

​#3 ​TRNR Interactive Strength Inc.  +2 spots

Recent News:

Interactive Strength's FORME Named an Exclusive Wellness Partner for Virgin Atlantic's New Clubhouse at LAX.

Excellent partnership with a massive company, jointly founded by part time "Shark" Richard Branson.

 They also had an incredible day Friday, Feb 28th after answering tough,--even rude--shareholder questions quite well.

Merging with Sportstech, a global company based in Germany,

and now acquiring an unnamed yet profitable ($15m/yr) company. Already they have acquired FORME & CLIMBR, the latter which recently received a 6 figure order. For these 2 new ones, no dilution is needed, only locked up shares, so no increase in float. A true "built in secure" money maker here.

NOW- The new BIG NEWS: TRNR attended a convention in

Las Vegas, and installed a CLMBR machine in Mandalay Bay Casino. The vibe is clear that the casinos may all order this,

due to the golf swing enhancement feature. It could set off a

flurry of orders in a hurry, as the word is "out" there.

 CEO Trent Ward (also co-founder of the company and has been actively involved in its growth and strategic direction in an aggressive, and marvelous fashion btw) promised more LV updates soon, too...likely this week.

 Trent is a tremendous company asset! TRNR's largest asset, though there are so many, is clearly its loyal shareholder following. We see it on a regular basis.

The volume lead the entire nanocap side of the stock market a few days there, and does so in a flash. We see jumps of .50/sh

in mere seconds with this one. 

With all the thousands of stocks out there, we have to pick the one most likely to 10x in a week to make #1.

Seeing the 80.47% short ratio, 347% borrow fee, LV PR

catalysts, double "dilution free" mergers, $33.73 Book Value

pre merger ($90+ per share post mergers!)

as confirmed by Finviz-- and has a tiny 1.5 million float.

The only reason for the fall from #1 last week is the slow

movement lately, discord in Europe (Sportstech's home) may be the reason, or unsettled merger dates.

 Curr=$.736 PT =$3.75 (509% realistic upside potential.)

​

#4 ATPC Agape ATP Corporation   -3 spots

 Folks, we've reported on quite a few stocks over the years.

 We've evaluated and predicted some high fliers in our day,

TPST (Oct '23) .17 to $8 over 3 days/ XTIA 5x in one day, HOLO before it's $1.50/sh to $113/sh run, and many, many others.  

      This one has the most potential of any stock we've seen.

--EVER. If it hit $200, we would not be surprised.

 The potential here is so overwhelming, yet REAL:

--SIGNED CONTRACTS IN HAND--it made our heads spin.

 

 So--To do our "Deep Dive DD" we dug in--and studied, and asked tough questions to answer the 7 normal, and "important to ask" questions the investing public has:

 

1) "Is this for real?"

2) "Can they fulfill the contract?"

3) "Did the company have "Insider Buying" right before the PR?" 

4) "Is the Insider Ownership enough to make it a safe investment?"

5) "What will be the new Book Value of the company, will it be significant?"

6) Is the float low enough for really quick moves up?

7) Is it "Tariff Turmoil" proof?​

 

1) "Is this for real?"

YES. 100%. All proper docs have been filed with the S.E.C.

Then came last Thursday's PR:  

"Agape ATP Corporation Secured Landmark Jet Fuel Supply Agreement with Swiss One Oil & Gas AG"

$12.312 billion in jet fuel & $12.1 billion in diesel, dual commodity 2 yr contract was signed.

 That totals $24,412,000,000 over 2 years, one month was already completed. (March).

It's real, folks, --Signed and Notarized--... You can view it in their April 3rd 8-K filing...Click Here

 

Let's explore their EN590 10 PPM diesel:

​

EN590 10PPM diesel is produced through a sophisticated refining process designed to achieve ultra-low sulfur content (10 parts per million). Here's a simplified overview of the production process:

1. Crude Oil Distillation: Crude oil is heated and separated into fractions based on boiling points. The diesel fraction is extracted for further refining.

2. Hydrodesulfurization (HDS): This critical step involves treating the diesel fraction with hydrogen gas under high pressure and temperature in the presence of a catalyst. Sulfur compounds are converted into hydrogen sulfide, which is removed, leaving the diesel with low sulfur levels.

3. Refining and Blending: The desulfurized diesel is further refined and blended with additives like cetane improvers, lubricity enhancers, and detergents to enhance engine performance, fuel stability, and reduce emissions.

4. Quality Control: Rigorous testing ensures compliance with EN590 standards, including sulfur content, cetane number, density, viscosity, and flash point.

This process results in cleaner-burning diesel fuel that meets stringent environmental regulations & improves engine efficiency.

 

 2) "Can they fulfill the contract?"

Supply and contract fulfillment are not a problem as ATPC Green Energy sources its diesel from many international suppliers as part of its structured agreements that are already in place.

 They've already fulfilled their March "trial" perfectly, thus thee

full contract.

FYI, for no hiccups: ATPC GE ensures compliance with global quality standards, with inspections conducted by the SGS to meet ASTM/IP international benchmarks.

 

What is the SGS you ask?

​

 SGS (Société Générale de Surveillance) is a Swiss multinational company headquartered in Geneva, Switzerland. It specializes in inspection, verification, testing, and certification services. SGS operates globally, providing services across industries such as agriculture, food, chemicals, construction, consumer goods, energy, and more.

The company ensures compliance with international standards, helping businesses meet regulatory requirements and improve quality. Contract fulfillment is assured, thus #3:

 

3) "Did the company have Insider buying right before the PR?" 

 

March 5th the company took in $23 million of mostly private investment money, so no dilution fears here.

(Per DilutionTracker: (cash burn is "pre $24b contract").

The company has 107.3 months of cash left based on quarterly cash burn of -$0.68M and estimated current cash of $24.3M.)

 

Moreover, these numerous Schedule 13-G filings speak to the reality of the contracts, and the excitement to own

large pieces of this company now-- before word gets "out"

and the reality "sinks in".

 

The mark of a company about to skyrocket in value is a sudden flurry of insider buying:

 

Sudden INSIDER buying on 3-5-25:

 

Vanguard DHL 3,017,600 shares

Global Fartech Ltd 3,450,000 shares

Nexus IGL 3,036,000 shares

Evergreen Strategic CHL  3,013.000 shares

Lesser Panda Ltd  3,680,000 shares

Blue Horizon CL 3,026,800 shares

Global Ascend VL 3,022,200 shares

Oceanic EPL 3,031,400 shares

=25,277,000 shares.

6.3+ M shares are held by the company and other smaller investor groups, the most notable is the NYSE listed Swiss giant

UBS Group AG (UBS).

UBS has an $86 billion market cap, they only invest in upward facing companies.  

​

4) "Is the I.O. enough to make it a safe investment?"

 The Stock Market has been in flux right now, experts call it a "Correction". A Correction is where overvalued stocks get sold off (why Tesla is collapsing, sorry Elon) and folks move their money

to the Bond Market, or severely undervalued stocks. Enter ATPC.

Sitting at a 63.21% Insider ownership, (all new money, too, btw)

Think Amazon--similar investor faith at 64.46%, it's just that their BV is just $27, why the 2 month decline from $242 to $171.

Using the stomped on metrics of Amazon, if we could transpose the to ATPC that would make ATPC $610.40/sh right now.

The high AMZN number of February would have made it $863.85.

Don't believe it?  Do the math. It's all there in public domain.

​

5) "What will be the new Book Value of the company?"

 It was about $24 million in book value pre-contract, let's add on:

$1,017,000,000 per month, on average, in new revenue.

​

In March, ATPC's "Fuel Trials" brought in $362 million in revenue...from SwissOne alone.

How about profit?

 

The standard profit margin in the diesel industry can vary depending on factors like market conditions, production costs, and regional demand. Typically, net profit margins for petroleum-based diesel hover around 5-10%, plus the specialty refining costs for green energy standards.

 

So let's call it a 5% profit margin, using a "low number", all things considered. A very fair, if not understated, assessment.

That's $50 million/month plus what their other businesses (heath & wellness, solar, industrial pumps, etc) do, (which Finviz says is growing 10.46% btw.)

 

That's $18.1 million in profit for March, from the new contract alone.

 

BUT think about this---

Have you seen the PLUMMET in oil prices lately?

With OPEC ramping up production, and Trump's tariffs disrupting the world markets, this GREATLY helps ATPC SAVE on raw fuel costs...while their selling price remains!

 

That's $50,850,000 per month in profit at least, using our "low numbers" - starting in April. Not including any other growth, which could also happen since major player SwissOne stepped up, others may jump in to match and keep pace.

 

 To find the P/E ratio in the industry, to determine fair industry book value, let's look to 2 industry giants, Exxon (XOM) and BP (BP). They display 7.85 & 7.88 ratios respectively. So we can safely assume their avg is a safe standard ratio to use...7.865.

 

Let's do the math to figure BV:

 We take EPS x 7.865. EPS=Annual earnings divided by the OS, 50.01 M. AE will be $610,200,000.

Div by the OS = $12.20/sh. x 7.86 - $95.90/share book value.

 Hold on, add on the .48/share current BV from the $24m:

$96.38 will be the new BV. Not in 2 years, NOW. The full contract started April 1, March was the trial period.

 The stock closed after market on Friday at $1.22. 

OMG. 7,900% "in a signed 2 yr contract" UPSIDE.

Remember folks, we used the "low" numbers in our figuring, (you read that, right?)

​

6) Is the float low enough for really quick moves up?

 Sitting at just 18.4 million, it absolutely is. Although not a tiny

float like BDRX, our #5, that one has uncertainty, if they fail on their FDA decision, they could plummet. ATPC has the contract,

no uncertainty here. 63%+ new insider buying, no uncertainty here. 50 to 60 million is usually the float wall for limiting quick upward movements, ATPC is well below that.

​

7) Is it "Trump's Tariff Turmoil" proof?

Absolutely, 100% "Trump's Tariff Turmoil" proof.

Sales are from Malaysia to the rest of Asia & Switzerland.

As we wrote, the $24.418 Billion contract is all to Switzerland.

​

Why the 3 spot drop you ask?

Although the math is there, the stock jumped 80% since we first reported this, investors are leary of Asian companies' claims,

pure and simple.

 Curr=$2.22 PT =$9.38 (422% realistic upside potential.)

​

#5 ​MIST Milestone Pharmaceuticals Inc.  -2 spots

 Folks jumped the gun 3 Fridays ago after a CRL was issued

to MIST from the FDA.

For those who can read and comprehend, it's really good news for the near future:

"The FDA did not raise any concerns regarding etripamil clinical safety or efficacy data and highlighted two key Chemistry, Manufacturing and Controls (CMC) issues to be addressed:

• Company to submit additional information on nitrosamine impurities based on new draft guidance issued after the NDA submission; and

• An inspection is required at a facility that performs release testing for etripamil, to ensure it is in compliance with Current Good Manufacturing Practices. The facility changed ownership during the review of the NDA.

“We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help patients with PSVT. Our team is evaluating the feedback provided and intends to request a Type A meeting to discuss the issues raised in the CRL,” said Joe Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. " "

  Safety & Efficacy data are the tough ones. MIST passed those tough tests....the rest will be fixed. 

Clearly more cash on hand than MC: (Per DilutionTracker:

"The company has 26.1 months of cash left based on quarterly cash burn of -$7.21M and estimated current cash of $62.7M."

MIST is an incredible bargain which will ultimately receive their

FDA approval for this truly great inhalant.

Curr=$1.28 PT =$4.51 (352% realistic upside potential.)

​

​​​

​